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Background: Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA). The
risk of aspirin intolerance is higher in people with rhinosinusitis than in those without it.
Recently, the role of transforming growth factor b1 (TGFb1) in the pathogenesis of chronic
rhinosinusitis has come under investigation. The goal of this study was to evaluate the
association of TGFb1 gene polymorphism with an AIA phenotype in the Korean population.
Methods: A promoter polymorphism of the TGFb1 gene, TGFb1-509C4T, and a coding
polymorphism (L10P), were genotyped in 203 patients with AIA, 324 patients with aspirin-
tolerant asthma (ATA), and 456 normal controls (NC). Serum TGFb1 levels were determined
by ELISA.
Results: The TGFb1-509C4T polymorphism was not significantly associated with the AIA
phenotype; however, a significant association with the prevalence of rhinosinusitis in AIA
(P ¼ 0:012), but not in ATA (P40:05), was observed. When stratified by the presence of
rhinosinusitis, the frequency of Tallele carriers (CTor TT genotype) of TGFb1-509C4Twas
significantly higher in AIA (87.1%) compared to ATA (52.9%, Po0:001, OR ¼ 6.0, 95%
CI ¼ 3.3–11.1). In addition, AIA patients carrying the TGFb1-509T allele showed a lower
serum TGFb1 level compared to AIA patients carrying the TGFb1-509 CC genotype,
especially when stratified by the presence of rhinosinusitis (P ¼ 0:002).Elsevier Ltd. All rights reserved.
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TGFb1 promoter polymorphism in AIA 491Conclusion: Our results show that the TGFb1 polymorphisms are not associated with the
AIA phenotype in the Korean population, but may contribute to the development of the AIA
phenotype with rhinosinusitis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Aspirin-intolerant asthma (AIA) is a clinical syndrome
characterized by eosinophilic rhinosinusitis, nasal polyposis,
aspirin sensitivity, and asthma.1–3 AIA has been regarded as a
distinct syndrome from allergic asthma. This condition is
most commonly found in middle-aged female asthmatic
patients with chronic rhinosinusitis and/or nasal polyps, and
there is no relationship with atopy.3–5 Up to 70% of patients
with AIA also have nasal polyps, and the incidence of
rhinosinusitis identified by radiography in AIA may be up to
90%. Recent studies examining the role of transforming
growth factor b1 (TGFb1) in chronic rhinosinusitis and nasal
polyps have demonstrated increased transcription of TGFb1
in nasal polyp or sinus tissue of patients with chronic
rhinosinusitis.6,7 We previously reported that eosinophils are
more activated in nasal polyp tissue of AIA patients than in
tissue of aspirin-tolerant asthma (ATA) patients8 and that
the degree of eosinophilic inflammation of nasal polyp tissue
is related to the TGFb1 level.9
The TGFb1 gene is located on chromosome
19q13.1–13.2,10 a genomic region that was linked to asthma
in a genome-wide scan, and plays an important role in
airway inflammation and remodeling.11 TGFb1 is strongly
expressed in response to inflammation of the nasal mucosa
and in allergic rhinitis, but not in normal nasal mucosa.12
TGFb1 may also contribute to eosinophilic inflammation of
nasal polyp tissue.6–9 The mRNA levels of TGFb1 in
eosinophils are increased in patients with severe asthma
compared to mild asthma,13 increased in the bronchoalveo-
lar lavage fluid of asthmatics compared to those of non-
asthmatics, and further increased in response to allergen
challenge.14 Several polymorphisms in the TGFb1 gene are
associated with the asthmatic phenotype.15,16 However,
there are no published data on genetic polymorphisms of
TGFb1 in AIA. In this study, we present the first investigation
on the effect of TGFb1 polymorphism on AIA and evaluate
the possible role of TGFb1 polymorphism in the association
between AIA and rhinosinusitis in the Korean population.Materials and methods
Subjects
Three subject groups (203 patients with AIA, 324 patients
with ATA, and 456 normal controls (NC)) were enrolled from
Ajou University Hospital and Soonchunhyang University
Hospital in Korea. The diagnosis of AIA was based on a
positive response to a lysine–aspirin (L–ASA) bronchoprovo-
cation test, which was performed with increasing doses of
ASA (75–300mg/ml Althargyl; Arthromedica, Switzerland)
according to a previously described modified method.17 A
change in the forced expiratory volume in 1 s (FEV1) wasfollowed for up to 5 h after the last dose of the aspirin
challenge. The ASA-induced change (%) in FEV1 was
calculated as the percentage of post-challenge FEV1 to
pre-challenge FEV1. Methacholine bronchial challenge tests
were performed as previously described.17 NC were
recruited from the general population answering negatively
to a screening questionnaire for respiratory symptoms; had
no past history of aspirin hypersensitivity and had a FEV1
greater than 80% predicted; PC20 methacholine greater than
25mg/ml; and normal findings on simple chest radiograms.
Atopy was defined as one or more positive reactions to a skin
prick test using 12 common aeroallergens (Bencard, Brent-
ford, UK) with histamine and saline controls. Total IgE was
measured using the UniCAP system (Pharmacia Diagnostics,
Uppsala, Sweden). The presence of rhinosinusitis and nasal
polyps were evaluated using a paranasal sinus (PNS) X-ray
and rhinoscopy. All subjects gave informed consent, and the
study was approved by the institutional review board of Ajou
University Hospital, Suwon, Korea. The clinical character-
istics of the study subjects are summarized in Table 1. There
were significant differences in mean age, atopic status,
and total serum IgE level between the AIA and NC groups
(all Po0:001). Between the AIA and ATA groups, there
were significant differences in PC20 methacholine and the
presence of rhinosinusitis and a nasal polyp (P ¼ 0:032;
o0:001, and o0.001, respectively).
Genotyping of TGFb1 polymorphism
Two SNPs in the TGFb1 gene (-509C4T and L10P) were
genotyped using a single base extension method. Sequences
of amplifying and extension primers for TGFb1-509C4T and
TGFb1 L10P polymorphisms were used for genotyping of
SNPs according to previously described methodology.18
Primer extension reactions were performed with the SNaP-
shot ddNTP primer extension kit (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s instructions.
ELISA for TGFb1
The measurement of TGFb1 in serum samples was performed
by ELISA (R&D Systems, Inc., Minneapolis, MN, USA). Before
measuring the level of TGFb1, the serum samples were
treated with acid to convert the inactive form of TGFb1 into
the active form. After neutralizing the sample with sodium
hydroxide, TGFb1 was measured according to the manufac-
turer’s instructions.
Statistical analysis
A significant departure of genotype frequency from the
Hardy–Weinberg equilibrium (HWE) at each SNP was tested
by w2 analysis. A difference in genotype frequency between
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Table 1 Clinical characteristics of the study subjects.
AIA ATA NC P-value
(n ¼ 203) (n ¼ 324) (n ¼ 456) AIA vs. ATA AIA vs. NC
Age (year)y 42.7714.1 41.8714.4 33.4714.7 0.504 o0.001
Sex (male) 83 (40.9%) 126 (38.9%) 210 (46.1%) 0.649 0.126
Atopy 103/183 (56.3%) 161/262 (61.5%) 38/292 (13.0%) 0.282 o0.001
Asthma duration (year)y 6.275.8 4.975.9 NA 0.037 NA
FEV1 (%)
y 80.1728.3 84.6721.8 NA 0.058 NA
PC20 methacholine (mg/ml)
y 5.078.1 6.979.1 NA 0.032 NA
Log serum total IgE (IU/ml)y 2.270.5 2.270.6 1.670.6 0.916 o0.001
Rhinosinusitis (presence/total) 131/161 (81.4%) 189/313 (60.4%) NA o0.001 NA
Nasal polyp (presence/total) 72/147 (49.0%) 10/193 (5.2%) NA o0.001 NA
n, number of patients; NA, not applicable.
AIA, ASA-intolerant asthma; ATA, ASA-tolerant asthma; NC, normal controls.
yThis value was presented as mean7SD.
Table 2 Allele and genotype frequencies of the TGFb1-509C4T.
Genotype AIA ATA NC P-valuey
(n ¼ 203) (n ¼ 324) (n ¼ 456) AIA vs. ATA AIA vs. NC
CC 50 (24.6%) 87 (26.9%) 130 (28.5%) 0.324 0.428
CT 98 (48.3%) 162 (50.0%) 215 (47.1%) 0.299 0.695
TT 55 (27.1%) 75 (23.1%) 111 (24.3%) 0.566 0.364
q 0.512 0.481 0.479 0.323 0.417
n, number of patients; q, minor allele frequency.
AIA, aspirin-intolerant asthma; ATA, aspirin-tolerant asthma; NC, normal controls.
yEach P-value was calculated with co-dominant, dominant and recessive models. Logistic regression analysis was used to control for
age and sex as covariables.
S.-H. Kim et al.492the case and control was assessed by a w2-test and the
calculation of odds ratios (OR) with 95% confidence intervals
(CI). Contingency tables (2 2) and w2-tests were used to
assess differences in TGFb1 polymorphism and the preva-
lence of rhinosinusitis. Logistic regression models were used
for analyzing SNPs and haplotypes controlling for age and
sex as covariates with three alternative models (codomi-
nant, dominant, and recessive). Differences in the mean
value of the phenotypic characteristics within AIA patients
were compared using ANOVA and a t-test. Statistical
analyses were performed using SPSS v.11 (SPSS Inc.,
Chicago, IL, USA). The significance level was set at Po0:05.Results
We performed a genetic association study of the TGFb1 gene
(TGFb1-509C4T) polymorphism in three groups of study
subjects classified as AIA, ATA, and NC. No significant
differences in the allele and genotype frequencies of
TGFb1-509C4T polymorphism were observed among the
three study groups (Table 2). The frequency of the non-
synonymous polymorphism of TGFb1 gene at codon 10
(TGFb1 L10P) was also not significantly different amongthe groups (data not shown). Asthma-associated quantita-
tive phenotypes such as atopy, serum total IgE level, initial
baseline FEV1, and PC20 methacholine values were evaluated
for any association with the promoter polymorphism of the
TGFb1 gene (Table 3). Although no significant associations of
TGFb1-509C4T polymorphism with clinical parameters
were observed, the TGFb1-509C4T polymorphism was
significantly associated with the prevalence of rhinosinusitis
within the AIA group (P ¼ 0:012). No significant associations
were noted for the TGFb L10P polymorphism for any
phenotype (P40:05; data not shown). Further analysis
revealed that the distribution of the TGFb1-509C4T
polymorphism in AIA patients and ATA controls stratified by
the presence of rhinosinusitis was significantly different
(Po0:001, OR ¼ 6.000, 95% CI ¼ 3.253–11.067; Table 4);
individuals carrying the TGFb1-509Tallele with rhinosinusitis
were found significantly more often in AIA (87.1%) than in
ATA (52.9%). Furthermore, a significant association between
the serum TGFb1 level and the TGFb1-509C4T polymorph-
ism was also noted (P ¼ 0:002; Table 3 and Fig. 1). Within
AIA patients, serum TGFb1 levels were significantly different
according to the TGFb1-509C4T polymorphism (Fig. 1A).
The level of serum TGFb1 in AIA patients carrying the
TGFb1-509 CT or TT genotype was lower compared to the
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Table 4 Distribution of TGFb1-509C4T polymorphism
in AIA patients and ATA controls stratified by the presence
of rhinosinusitis.
Rhinosinusitis AIA ATA P-value
AIA vs. ATA
CC Presence 30 (68.2%) 44 (60.3%) 0.433
Absent 14 (31.8%) 29 (39.7%)
N 44 73
CT or TT Presence 101 (87.1%) 101 (52.9%) o0.001y
Absent 15 (12.9%) 90 (47.1%)
N 116 191
AIA; aspirin-intolerant asthma, ATA; aspirin-tolerant
asthma.
yOR ¼ 6.000 (95% CI ¼ 3.253–11.067).
TGFb1 promoter polymorphism in AIA 493AIA patients carrying the TGFb1-509 CC genotype. The
effect was more clearly evident in the AIA patients with
rhinosinusitis (Fig. 1B).Discussion
TGFb1 is a multifunctional cytokine with both immunosup-
pressive and pro-inflammatory effects.19–21 TGFb1 contri-
butes to the pathogenesis of asthma and is associated with
disease severity by enhancing the deposition of the
extracellular matrix.13,22 Additionally, mRNA levels of TGFb1
are up-regulated in bronchial asthma.22,23 Thus, TGFb1 is
likely to promote airway remodeling and irreversible airway
obstruction.24–26
The -509C4T promoter polymorphism of TGFb1 has been
reported to influence the expression of the TGFb1 gene.28–30
This effect is thought to occur through an enhancement of
the binding affinity of the YY1 transcription factor, leading
to increased TGFb1 transcription and higher circulating
concentrations of TGFb1 in the plasma. This polymorphism
has been associated with asthma27 and asthma severity.31
However, the role of this polymorphism in the pathogenesis
of AIA has not been addressed.
In this study, we failed to demonstrate any relationship
between TGFb1 polymorphism and clinical characteristics of
asthma such as the total serum IgE level, PC20 methacholine,
and basal FEV1 values. However, we did observe a significant
association between the TGFb1-509C4T polymorphism and
the prevalence of rhinosinusitis, a typical characteristic of
AIA, with patients carrying the T allele having a higher
prevalence of rhinosinusitis. When stratified by the presence
of rhinosinusitis, the genotypic distribution of the promoter
polymorphism was significantly different between the AIA
and ATA groups; the frequencies of the -509 CT or TT
genotype were higher in the AIA (87.1%) than in the ATA
patients (52.9%) with rhinosinusitis. We previously demon-
strated a close correlation between eosinophil cationic
protein (ECP) levels and the TGFb1 level in nasal polyp tissue
of AIA patients, suggesting that TGFb1 may contribute to the
eosinophilic inflammation of the nasal polyp.7,9 The current
findings suggest that there is a contribution of the TGFb1-
509C4T polymorphism to the susceptibility to AIA with
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Figure 1 Association of serum TGFb1 level with the promoter polymorphism: (A) serum TGFb1 level within AIA patients; and (B)
serum TGFb1 level within AIA patients having rhinosinusitis.
S.-H. Kim et al.494rhinosinusitis and that the comorbidity of AIA and rhinosi-
nusitis may result from a common genetic factor, i.e., the
polymorphism of TGFb1. In accord with previous stu-
dies,28,30 the promoter polymorphism also showed a
significant association with serum TGFb1 levels; AIA patients
carrying the TGFb1-509 CT or TT genotype showed a lower
serum level of TGFb1 compared to AIA patients carrying the
TGFb1-509 CC genotype; this difference was highly signifi-
cant when stratified by the presence of rhinosinusitis.
Studies have recently suggested that TGFb1 plays a major
role in chronic rhinosinusitis32,33 due to increased expression
of TGFb1 in patients with rhinosinusitis and a nasal polyp32
and the abundant expression of TGFb1 at both the mRNA and
protein levels in the nasal mucosa of patients with chronic
rhinosinusitis33 correlating with the ECP level.9 These
findings suggest that TGFb1 production in AIA patients may
be localized and compartmentalized within the nasal
mucosa and/or polyp tissues with strong eosinophilic
inflammatory responses. The local production and release
of TGFb1 in nasal mucosa and polyp tissues may serve either
to localize the inflammatory response to nasal mucosa or as
a local tissue response to eosinophilic inflammation.
In this study, we observed that the Tallele was associated
with lower plasma levels of TGFb1. This finding contradicts a
previous study of this polymorphism in which TGFb1
concentrations in plasma were observed to be approxi-
mately twice higher in TT compared to CC homozygotes.30
There are several factors that may account for the
discrepancy. In the present study, we recruited patients
with AIA, and TGFb1 was only detected in its active form. In
contrast, the study of Grainger et al. consisted of
postmenopausal women and both the active and latent
forms of TGFb1 were studied. In addition, there was no
difference in clinical severity according to this polymorph-
ism in our study, so a possibility of glucocorticoid systemic
effect seems to be very low. We speculated that these
findings might be derived from that TGFB1 is localized and
compartmentalized within the nasal mucosa of AIA patients
with rhinosinusitis. However, the exact mechanism respon-
sible for the decreased production of TGFb1 in the sera of
AIA patients with rhinosinusitis and/or a nasal polyp needs
further investigation.
In conclusion, TGFb1 promoter polymorphism is not
associated with an AIA phenotype in the Korean population;however, the TGFb1-509C4T polymorphism may con-
tribute to the development of the AIA phenotype with
rhinosinusitis.References
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